Methylmalonyl acidemia: from mitochondrial metabolism to defective mitophagy and disease

Autophagy. 2020 Jun;16(6):1159-1161. doi: 10.1080/15548627.2020.1753927. Epub 2020 Apr 22.

Abstract

Methylmalonic acidemia (MMA) is an autosomal recessive inborn error of metabolism due to the deficiency of mitochondrial MMUT (methylmalonyl-CoA mutase) - an enzyme that mediates the cellular breakdown of certain amino acids and lipids. The loss of MMUT leads to the accumulation of toxic organic acids causing severe organ dysfunctions and life-threatening complications. The mechanisms linking MMUT deficiency, mitochondrial alterations and cell toxicity remain uncharacterized. Using cell and animal-based models, we recently unveiled that MMUT deficiency impedes the PINK1-induced translocation of PRKN/Parkin to MMA-damaged mitochondria, thereby halting their delivery and subsequent degradation by macroautophagy/autophagy-lysosome systems. In turn, this defective mitophagy process instigates the accumulation of dysfunctional mitochondria that spark epithelial distress and tissue damage. Correction of PINK1-directed mitophagy defects or mitochondrial dysfunctions rescues epithelial distress in MMA cells and alleviates disease-relevant phenotypes in mmut‒deficient zebrafish. Our findings suggest a link between primary MMUT deficiency and diseased mitochondria, mitophagy dysfunction and cell distress, offering potential therapeutic perspectives for MMA and other metabolic diseases.

Keywords: Cell damage; inherited metabolic disorders; kidney tubule; metabolism; mitochondria; mitophagy; oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autophagy
  • Methylmalonyl-CoA Mutase
  • Mitochondria
  • Mitophagy*
  • Ubiquitin-Protein Ligases
  • Zebrafish*

Substances

  • Ubiquitin-Protein Ligases
  • Methylmalonyl-CoA Mutase

Grants and funding

We are grateful to the European Reference Network for Rare Kidney Diseases (ERKNet) – project ID N° 739532; the Cystinosis Research Foundation (Irvine, CA, USA); the Swiss National Science Foundation (310030_189044); the clinical research priority programs (KFSP) radiz (Rare Disease Initiative Zurich) and Molecular Imaging Network Zurich (MINZ) at the University of Zurich; the Swiss National Centre of Competence in Research (NCCR) Kidney Control of Homeostasis (Kidney.CH) for support and Junior Grant (to A.L.) and the Wolfermann–Nägeli Shiftung.